Tenax Therapeutics, Inc.
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol
Source
From GlobeNewswire
23 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
FACT II Acquisition Corp.
FACT II Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
Star Equity Holdings, Inc.
Star Equity Holdings, Inc.
Acquisition Adds Established Enterprise Client Relationships, Experienced U.S. Sales Leadership, and Back-Office Synergies
Progyny, Inc.
Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income
Carriage Services Inc
CARRIAGE SERVICES INC
Carriage Services Announces Third Quarter 2026 Results, Updates 2026 Guidance
Cytek Biosciences, Inc.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Pacific Biosciences Of California, Inc.
PacBio Announces Third Quarter 2026 Financial Results
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Twin Disc Inc
Twin Disc Announces First Quarter Results
Riot Platforms, Inc.
Riot Platforms Reports Third Quarter 2026 Financial Results and Strategic Highlights
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28…
Biocryst Pharmaceuticals Inc
BioCryst Reports Third Quarter 2026 Financial Results
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —
Geron Corp
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Shoals Technologies Group, Inc.
Shoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2026
–Quarterly Revenue of $195.3 million –
Ridgepost Capital, Inc.
Ridgepost Capital Reports Third Quarter 2026 Financial Results
Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027